Agios Pharma(DE:8AP)
€27.20+0.20 (+0.74%)
DE:8AP
Agios Pharma stock drug pipeline
€27.20
At close:+0.20 (+0.74%)
Agios Pharma (8AP) Drug Pipeline
0 Followers
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Agios Pharmaceuticals (DE:8AP) have in its pipeline
Agios Pharma DE:8AP is currently developing the following drugs: Mitapivat, Ag-348, Ag-181, Ag-236, Tebapivat, [14C]-Tebapivat, [13C2,15N3]-Tebapivat, Midazolam, Mitapivat, Pyrukynd, Ag-348, Mitapivat, Mitapivat, Pyrukynd, Ag-348, Ag881, Ag-348. These drug candidates are in various stages of clinical development as the company works toward FDA approval.

